Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12590

1.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
2.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

PMID:
30157388
3.

Research Uncovers How Commensal Bacteria Contribute to Multiple Sclerosis.

Hampton T.

JAMA. 2018 Aug 7;320(5):429-430. doi: 10.1001/jama.2017.12863. No abstract available.

PMID:
30087987
4.

Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.

Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF.

Medicine (Baltimore). 2018 Jul;97(28):e11507. doi: 10.1097/MD.0000000000011507. Review.

5.

Are adverse outcome rates higher in multiple sclerosis patients after total hip arthroplasty?

Newman JM, Khlopas A, Sodhi N, Curtis GL, Sultan AA, George J, Higuera CA, Mont MA.

Bone Joint J. 2018 Jul;100-B(7):875-881. doi: 10.1302/0301-620X.100B7.BJJ-2017-1569.R1.

PMID:
29954205
6.

Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial.

Simone M, Viterbo RG, Margari L, Iaffaldano P.

BMC Neurol. 2018 Jun 8;18(1):82. doi: 10.1186/s12883-018-1087-3.

7.

A Cognitive Occupation-Based Programme for People with Multiple Sclerosis: A Study to Test Feasibility and Clinical Outcomes.

Reilly S, Hynes SM.

Occup Ther Int. 2018 May 2;2018:1614901. doi: 10.1155/2018/1614901. eCollection 2018.

8.

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I.

Expert Opin Drug Saf. 2018 Jul;17(7):709-717. doi: 10.1080/14740338.2018.1483330. Epub 2018 Jun 11. Review.

PMID:
29848085
9.

Determinants of Cognitive Impairment in Patients with Multiple Sclerosis with and without Atrophy.

Eijlers AJC, Meijer KA, van Geest Q, Geurts JJG, Schoonheim MM.

Radiology. 2018 Aug;288(2):544-551. doi: 10.1148/radiol.2018172808. Epub 2018 May 22.

PMID:
29786489
10.

Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights from Functional MRI.

Zivadinov R.

Radiology. 2018 Aug;288(2):552-553. doi: 10.1148/radiol.2018180719. Epub 2018 May 22. No abstract available.

PMID:
29786484
11.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.

PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018.

12.
13.

Effect of photobiomodulation treatment in the sublingual, radial artery region, and along the spinal column in individuals with multiple sclerosis: Protocol for a randomized, controlled, double-blind, clinical trial.

da Silva T, da Silva FC, Gomes AO, Viana AO, Gonçalves MLL, Rodrigues MFSD, Horliana ACRT, da Silva DFT, Chavantes MC, Fragoso YD, Branco LP, Motta LJ, Fernandes KPS, Mesquita-Ferrari RA, Bussadori SK.

Medicine (Baltimore). 2018 May;97(19):e0627. doi: 10.1097/MD.0000000000010627.

14.

Lower Aerobic Endurance Linked to History of Depression in Multiple Sclerosis: Preliminary Observations.

Chapman KR, Anderson JR, Calvo D, Pollock BS, Petersen J, Gerhart H, Ridgel A, Spitznagel MB.

J Neurosci Nurs. 2018 Jun;50(3):167-170. doi: 10.1097/JNN.0000000000000360.

PMID:
29727394
15.

Sexual Function in Young Individuals With Multiple Sclerosis: Does Disability Matter?

Calabrò RS, Russo M, Dattola V, De Luca R, Leo A, Grisolaghi J, Bramanti P, Quattrini F.

J Neurosci Nurs. 2018 Jun;50(3):161-166. doi: 10.1097/JNN.0000000000000367.

PMID:
29727393
16.

Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M; MAGNIMS Study Group.

Radiology. 2018 Aug;288(2):554-564. doi: 10.1148/radiol.2018172468. Epub 2018 May 1.

PMID:
29714673
17.

Acute responses of cytokines and adipokines to aerobic exercise in relapsing vs. remitting women with multiple sclerosis.

Majdinasab N, Motl RW, Mokhtarzade M, Zimmer P, Ranjbar R, Keytsman C, Cullen T, Negaresh R, Baker JS.

Complement Ther Clin Pract. 2018 May;31:295-301. doi: 10.1016/j.ctcp.2018.03.004. Epub 2018 Mar 14.

PMID:
29705471
18.

Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability.

Valsasina P, Aboulwafa M, Preziosa P, Messina R, Falini A, Comi G, Filippi M, Rocca MA.

Radiology. 2018 Jul;288(1):234-244. doi: 10.1148/radiol.2018172311. Epub 2018 Apr 17.

PMID:
29664341
19.

New biological agents in the treatment of multiple sclerosis.

Buc M.

Bratisl Lek Listy. 2018;119(4):191-197. doi: 10.4149/BLL_2018_035. Review.

PMID:
29663814
20.

Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Int J Mol Sci. 2018 Apr 16;19(4). pii: E1212. doi: 10.3390/ijms19041212. Review.

Supplemental Content

Loading ...
Support Center